3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
3
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
15
Prostatic Neoplasms, Castration-Resistant
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Uveal Melanoma
1
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Penile Neoplasms
1
Ovarian Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
20
atezolizumab
8
Nivolumab
8
Docetaxel
7
Carboplatin
6
cemiplimab
5
Immune Checkpoint Inhibitors
5
Radiotherapy
4
Paclitaxel
4
Filgrastim
4
Drug Therapy
4
fludarabine
3
durvalumab
3
Radiosurgery
3
Pemetrexed
3
Gemcitabine
3
Fluorouracil
3
Cyclophosphamide
3
Cisplatin
3
Cetuximab
3
Bortezomib
3
niraparib
2
motexafin gadolinium
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
aldesleukin
2
Tobacco Use Cessation Devices
2
Tetrahydrouridine
2
Taxes
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
niraparib
×
Genitourinary
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts